Gedeon Richter details specifications for Amdoal antipsychotic
Gedeon Richter Plc. has released documentation for Amdoal, an aripiprazole-based medication indicated for the treatment of schizophrenia and bipolar disorder.
Pharmaceutical company Gedeon Richter has published the clinical specifications for its medication, Amdoal. The drug, which utilizes the active ingredient aripiprazole, is prescribed for adult patients diagnosed with schizophrenia and type I bipolar disorder.
Amdoal is available in 10 mg and 15 mg tablets. The mechanism of action involves a combination of partial agonist activity at dopamine D2 and serotonin 5HT1a receptors, alongside antagonistic activity at serotonin 5HT2a receptors. Clinical data indicates that the drug is rapidly absorbed following oral administration, achieving steady-state plasma concentrations within approximately 14 days.
Pharmacokinetic analysis suggests that age, gender, smoking status, and renal impairment do not significantly alter the drug's metabolism. The substance is primarily metabolized in the liver. These details follow regulatory requirements for the use of antipsychotic agents in the designated patient population.